Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers (Tables)

Revenues from Contracts and Significant Customers (Tables)

9 Months Ended

Sep. 30, 2018

The Company has four marketed products, Targadox®, Exelderm®, Luxamend® and Ceracade®. Substantially all of the Company’s product revenues are recorded in the U.S. Substantially all of the Company’s collaboration revenues are from its collaboration with TGTX. Revenues by product and collaborator are summarized as follows (in thousands):

	Three months ended September 30, 2018		Nine months ended September 30, 2018
Targadox®	$	4,322	$	16,183
Other branded revenue		846		1,183
Total product revenues		5,168		17,366
TGTX		5		525
Total Revenue	$	5,173	$	17,891

Revenue From Contracts With Customers [Member]

Disaggregation of Revenue

The following presents National’s revenues from contracts with customers disaggregated by major business activity for the three months ended September 30, 2018:

($ in thousands)	For the Three Months Ended September 30, 2018		For the Nine Months Ended September 30, 2018
Revenues from customer contracts:
Commissions	$	28,397	$	85,422
Investment banking:
Underwriting		2,534		12,127
Private placement		13,567		26,866
Advisory		4,915		7,062
Other		–		156
Sub-total National revenue from contracts with customers		49,413		131,633
Other National revenue		9,107		33,428
Total National revenue	$	58,520	$	165,061